SEC Comment Letter for Twist Bioscience Corp (TWST) (CIK 0001581280) (TWST) — Apr 24, 2019

Twist Bioscience Corp (TWST) (CIK 0001581280)
Date: April 24, 2019 · CIK: 0001581280 · Accession: 0000000000-19-007541

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 24, 2019

Author

Emily M. Leproust

Form

UPLOAD

Company

Twist Bioscience Corp (TWST) (CIK 0001581280)

Letter

April 24, 2019 Emily M. Leproust Chief Executive Officer Twist Bioscience Corporation 455 Mission Bay Boulevard South, Suite 545 San Francisco, CA 94158 Re:Twist Bioscience Corporation Draft Registration Statement on Form S-1 Submitted April 18, 2019 CIK No. 0001581280 Dear Ms. Leproust: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

April 24, 2019
Emily M. Leproust
Chief Executive Officer
Twist Bioscience Corporation
455 Mission Bay Boulevard South, Suite 545
San Francisco, CA 94158
Re:Twist Bioscience Corporation
Draft Registration Statement on Form S-1
Submitted April 18, 2019
CIK No. 0001581280
Dear Ms. Leproust:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io